The dementias

Institut National de la Santé et de la Recherche Médicale, EMI 99-30, Hôpital La Colombière, Montpellier, France.
The Lancet (Impact Factor: 45.22). 12/2002; 360(9347):1759-66. DOI: 10.1016/S0140-6736(02)11667-9
Source: PubMed


Dementia affects about 5% of the elderly population over age 65 years and has an unexplained predominance in women and a low rate in some cultures. Different forms of dementia are now distinguished-Alzheimer's disease, dementia with Lewy bodies, frontotemporal dementia, and dementia secondary to disease, such as AIDS dementia. However, such nosological boundaries are being re-evaluated because different dementias are believed to have common underlying neuropathology. Neurochemical and neurobiological research has led to advances in understanding causes of dementia, and functional imaging has allowed identification of possible biomarkers; from these, a range of potential treatment approaches have arisen that focus on enhancement of neurotransmitter function, intervention at the level of amyloid production and deposition, and reduction of secondary risk factors such as hypertension, depression, and hypolipidaemia. Molecular diagnostic testing and genetic counselling for families with autosomal dominant early-onset dementia are new developments; however, this approach is not useful for late-onset dementia, in which the identified candidate susceptibility genes have a relatively small effect on risk. While fundamental research works towards new biological treatment strategies, much remains to be done in the area of disease management and the development of appropriate models of long-term care.

Download full-text


Available from: Simon Lovestone, Oct 10, 2015
133 Reads
  • Source
    • "The incidence of neurodegenerative disorders, particularly Alzheimer and Parkinson diseases, rapidly increases with age and, therefore, these pathologies represent important health challenges for all aging populations in the world (Ritchie & Lovestone, 2002). Currently, there is no disease-modifying treatment strategy for most neurodegenerative disorders. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Context: Finding effective therapies for neurodegenerative diseases is of utmost importance for the aging population. Plants growing in Iran are rich sources of antioxidants and active phytochemicals. Objective: The protective capacity of plants, with a special focus on those with reported antioxidant or neuroprotective potential or nervous system-related applications in folk medicine, was tested against oxidative stress-induced apoptosis. Materials and methods: Aerial parts of 20 plants including Carthamus, Salvia, and Stachys species were extracted with 80% methanol and dichloromethane and preincubated with neuronal PC12 cells for 3 h. Oxidative stress and apoptosis were induced by hydrogen peroxide (75 µM, 1 h exposure). Cell viability and intracellular reactive oxygen species (ROS) were measured by MTT and 2′,7′-dichlorofluorescein-diacetate (DCFH-DA) assays, respectively, while apoptosis was determined by annexin V-FITC/propidium iodide staining by a flow cytometer. Results: Eighty percent methanol extracts of Carthamus oxyacantha Bieb. (Asteraceae), Salvia santolinifolia Boiss. (Lamiaceae), and Salvia sclarea L. (Lamiaceae) at the concentration of 100 μg/ml showed significant neuroprotection in the MTT assay by 38.7, 34.7, and 39.5%, respectively, and inhibited intracellular ROS by 48.6, 61.9, and 61.4%, respectively. The first two extracts also significantly inhibited apoptosis. Dichloromethane extracts of C. oxyacantha and Stachys pilifera Benth. (Lamiaceae) at the concentration of 25 μg/ml showed neuroprotection by 27.5 and 26.5%, respectively, and inhibited ROS by 44.5 and 39.4%, respectively. Conclusion: The above-mentioned plants seem to have important biological activities and their further study may lead to the discovery of new natural therapeutics useful against disorders such as Alzheimer and Parkinson diseases.
    Pharmaceutical Biology 09/2014; 52(12). DOI:10.3109/13880209.2014.908394 · 1.24 Impact Factor
  • Source
    • "The global prevalence of dementia is increasing and it is predicted to affect over 80 million individuals worldwide by the year of 2040 [1]. The dementia syndrome includes a progressive deterioration of cognitive functions often accompanied by neuropsychiatric symptoms referred to as behavioral and psychological symptoms in dementia (BPSD) [2,3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The objective of this study was to examine the associations of agitation with the cerebrospinal fluid dementia biomarkers total-tau (T-tau), phosphorylated-tau (P-tau) and Aβ1-42. Methods One hundred patients (mean age ± SD, 78.6 ± 7.5 years) with dementia and neuropsychiatric symptoms, of whom 67% were female, were included. Agitation was measured using the Cohen-Mansfield Agitation Inventory (CMAI; 46.5 ± 11.8 points). Results Total CMAI correlated with T-tau [rs (31) = 0.36, p = 0.04] and P-tau [rs (31) = 0.35, p = 0.05] in patients with Alzheimer's disease (AD; n = 33) but not in the total dementia population (n = 95). Conclusions Our results suggest that tau-mediated pathology including neurofibrillary tangles and the intensity of the disease process might be associated with agitation in AD.
    08/2014; 4(2). DOI:10.1159/000363500
  • Source
    • "Acute and chronic neurodegenerative diseases, including stroke, traumatic brain injury (TBI), Alzheimer's disease (AD), and Parkinson's disease (PD), are illnesses associated with high morbidity and mortality, and few or no effective options are available for their treatment [1] [2]. These diseases result in acute, as well as gradual and progressive neurodegeneration , leading to brain dysfunction and neuronal death. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A wide variety of acute and chronic neurodegenerative diseases, including ischemic/traumatic brain injury, Alzheimer's disease, and Parkinson's disease, share common characteristics such as oxidative stress, misfolded proteins, excitotoxicity, inflammation, and neuronal loss. As no drugs are available to prevent the progression of these neurological disorders, intervention strategies using phytochemicals have been proposed as an alternative form of treatment. Among phytochemicals, isothiocyanate sulforaphane, derived from the hydrolysis of the glucosinolate glucoraphanin mainly present in Brassica vegetables, has demonstrated neuroprotective effects in several in vitro and in vivo studies. In particular, evidence suggests that sulforaphane beneficial effects could be mainly ascribed to its peculiar ability to activate the Nrf2/ARE pathway. Therefore, sulforaphane appears to be a promising compound with neuroprotective properties that may play an important role in preventing neurodegeneration.
    Oxidative medicine and cellular longevity 08/2013; 2013:415078. DOI:10.1155/2013/415078 · 3.36 Impact Factor
Show more